▼Moclobemide for depression
- 1 January 1994
- journal article
- Published by BMJ in Drug and Therapeutics Bulletin
- Vol. 32 (1) , 6-8
- https://doi.org/10.1136/dtb.1994.3216
Abstract
Moclobemide (Manerix - Roche), the first of a new class of antidepressant drugs, was launched in the UK last year. It is a reversible inhibitor of monoamine oxidase A, which the manufacturer claims is a "first line treatment for major depression". Is this claim justified?Keywords
This publication has 24 references indexed in Scilit:
- Five fatal cases of serotonin syndrome after moclobemide-citalopram or moclobemide-clomipramine overdosesThe Lancet, 1993
- A double-blind comparison of moclobemide and fluoxetine in the treatment of depressive disordersInternational Clinical Psychopharmacology, 1993
- An update of recent moclobemide interaction dataInternational Clinical Psychopharmacology, 1993
- Efficacy of moclobemide in different patient groups: a meta-analysis of studiesPsychopharmacology, 1992
- Interactions of moclobemide with concomitantly administered medication: evidence from pharmacological and clinical studiesPsychopharmacology, 1992
- Efficacy of reversible inhibitors of monoamine oxidase-A in various forms of depressionActa Psychiatrica Scandinavica, 1990
- Tolerability of moclobemide, a new reversible inhibitor of monoamine oxidase‐A, compared with other antidepressants and placeboActa Psychiatrica Scandinavica, 1990
- A Controlled Study of the Antidepressant Efficacy and Side Effects of ( — )-DeprenylArchives of General Psychiatry, 1989
- Clinical Pharmacology of Monoamine Oxidase InhibitorsClinical Neuropharmacology, 1986
- HYPERTENSIVE CRISIS DUE TO MONOAMINE-OXIDASE INHIBITORSThe Lancet, 1963